Epigenetics Drugs Market
Epigenetics Drugs Market Size, Share & Industry Analysis, By Drug Type (HDAC Inhibitors, DNMT Inhibitors, Others), By Application (Oncology, Metabolic Disorders, Autoimmune Disorders, Others), By Diagnostic Technology (PCR-based, Sequencing-based, Immunoassays, Others), By End User (Hospitals, Specialty Clinics, Research Institutes), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The global Epigenetics Drugs & Diagnostic Technologies Market is projected to grow at a CAGR of 16.8% from 2024 to 2031. The market value is expected to rise from YY billion USD in 2024 to YY billion USD by 2031. North America currently dominates the market, followed closely by Europe. Key metrics include increasing research and development activities, rising prevalence of cancer and other chronic diseases, and growing adoption of personalized medicine.
The market is expanding rapidly, owing to advances in epigenetic research, increased investment in drug discovery, and rising demand for tailored medicines. The incorporation of artificial intelligence and machine learning into epigenetic research is likely to drive market expansion over the forecast period.
Market Dynamics:
Increasing prevalence of cancer driving demand for epigenetic therapies
The rising global cancer incidence is a crucial driver of the epigenetics pharmaceuticals and diagnostic technologies industry. According to the World Health Organisation, cancer is the world's second biggest cause of death, with an anticipated 9.6 million deaths in 2018. Epigenetic changes play an important role in cancer formation and progression, making epigenetic treatments a promising approach to cancer treatment. For example, HDAC inhibitors have been proven to be effective in the treatment of a variety of haematological malignancies and solid tumours. The expanding understanding of epigenetic pathways in cancer has resulted in increased research and development activity in this area, boosting market growth.
Advancements in diagnostic technologies enhancing epigenetic research and clinical applications
Technological improvements in diagnostic platforms are propelling the epigenetics industry. Next-generation sequencing (NGS) technologies have revolutionised epigenetic research by allowing for high-throughput investigation of DNA methylation patterns and histone modifications. The development of increasingly sensitive and specific tests for detecting epigenetic markers has increased the accuracy of epigenetic-based diagnostics. For example, liquid biopsy approaches based on cell-free DNA methylation analysis have showed promise for early cancer identification and surveillance. These improvements broaden the applicability of epigenetic diagnostics in personalised medicine, resulting in increasing clinical use and market growth.
Regulatory challenges and high development costs hindering market growth
The complex regulatory landscape for epigenetic medications and diagnostics presents a significant barrier to commercial expansion. Regulatory bodies require significant clinical evidence to establish the safety and efficacy of epigenetic medicines, which can slow the licensing process and raise development costs. Furthermore, the exorbitant cost of epigenetic medication development, which is expected to be more than $1 billion per drug, deters certain pharmaceutical companies from engaging in this area. These constraints may limit the number of innovative epigenetic medicines entering the market, thus slowing total market growth.
Segment Overview:
HDAC inhibitors dominate the epigenetic drugs market segment:
HDAC (Histone Deacetylase) inhibitors now dominate the epigenetic medicines industry. These medications have demonstrated great efficacy in treating a variety of cancers, particularly haematological malignancies. The efficacy of HDAC inhibitors such as Vorinostat and Romidepsin in treating cutaneous T-cell lymphoma has cleared the path for their wider usage in other conditions.
Recent clinical trials have yielded promising results for HDAC inhibitors in combination therapy. For example, a phase II research published in the Journal of Clinical Oncology found that combining Entinostat, an HDAC inhibitor, with hormone therapy enhanced progression-free survival in advanced breast cancer patients. This has sparked considerable interest from pharmaceutical companies in developing novel HDAC inhibitors.
The oncology application sector has the biggest market share, owing to the high incidence of cancer and the expanding use of epigenetic treatments in cancer therapy. The American Cancer Society estimates that there will be 1.9 million new cancer cases identified in the United States in 2021. This high disease burden has fuelled research into cancer's epigenetic underpinnings, resulting in the development of new diagnostic tools and targeted treatments.
Regional Outlook:
North America leads the global epigenetics drugs and diagnostic technologies market:
North America leads the worldwide epigenetics market due to its advanced healthcare infrastructure, significant R&D expenditure, and favourable reimbursement regulations. The presence of large pharmaceutical and biotechnology businesses engaging in epigenetics research and drug development contributes to the region's leadership.
The United States, in particular, has experienced an increase in epigenetics research programs. The National Institutes of Health (NIH) has provided major funding for epigenetic research through programs such as the Roadmap Epigenomics Project, which has greatly enhanced our understanding of epigenetic pathways in human health and illness.
Recent collaborations between academic institutions and commercial entities have sped up epigenetic drug discovery in the region. According to Nature Communications, a collaboration between a top US institution and a biotechnology business resulted in the discovery of a novel epigenetic target for treating aggressive prostate cancer.
The FDA's clearance of new epigenetic medicines has accelerated market expansion in North America. In 2020, the FDA authorised Tazverik (tazemetostat), an EZH2 inhibitor, for the treatment of epithelioid sarcoma, a significant step forward in epigenetic medication research.
Competitive Intelligence:
The market for epigenetic medications and diagnostic technologies is very competitive, with significant technological breakthroughs. To retain their market positions, key firms are focussing on strategic partnerships, mergers and acquisitions, and product portfolio expansion.
Leading firms in this field include Illumina, Inc., Qiagen N.V., Abcam plc, and Merck KGaA. These firms have made considerable investments in R&D to create novel epigenetic technologies and treatments. For example, Illumina's invention of high-throughput sequencing technology has transformed epigenetic research by enabling thorough investigation of DNA methylation profiles.
Companies specialising in epigenetic medications, such as Celgene Corporation (now part of Bristol-Myers Squibb) and Eisai Co., Ltd., have experienced significant market share increase as a result of the success of their HDAC inhibitor treatments. Celgene's Istodax (romidepsin) and Eisai's Halaven (eribulin mesylate) are effective in treating particular forms of lymphoma and breast cancer, respectively.
The market has also seen an infusion of biotechnology businesses focused on novel epigenetic targets and technologies. These smaller startups frequently collaborate with larger pharmaceutical corporations to move their treatment concepts through clinical trials, resulting in a dynamic and competitive landscape.
Financial performance varies among important actors, with larger, more diverse corporations typically demonstrating more steady revenue streams. However, companies with successful epigenetic medications in their portfolios have experienced tremendous sales increases in recent years. The industry is projected to further consolidate as larger pharmaceutical companies look to acquire promising epigenetic technologies and medication prospects.
Analyst Opinion:
The market for epigenetic medications and diagnostic technologies is expected to rise significantly in the future years, owing to a better knowledge of epigenetic pathways in disease development and increased demand for personalised therapy. The field of epigenetics holds enormous potential for producing targeted therapeutics with fewer side effects than traditional treatments.
Epigenetics is combining with other cutting-edge technologies, such as CRISPR-Cas9 gene editing and artificial intelligence, to create an intriguing market trend. This integration is expected to speed up drug discovery and lead to more accurate diagnostic tools. Another promising field of research is the development of epigenetic biomarkers for early illness detection and therapy response monitoring.
However, there are still hurdles in converting epigenetic research into clinically useful medicines. The complexity of epigenetic pathways, as well as the possibility of off-target consequences, must be carefully considered during medication development. Furthermore, the high cost of epigenetic medicines may limit availability, necessitating novel pricing and reimbursement techniques.
Despite these challenges, the epigenetics market is predicted to grow rapidly, driven by continuous research, technological breakthroughs, and more investment in this discipline. Companies who can successfully negotiate the regulatory landscape while demonstrating demonstrable clinical benefits for their epigenetic treatments are likely to emerge as market leaders in this rapidly evolving industry.
Major Players:
-
Illumina, Inc.
-
Qiagen N.V.
-
Abcam plc
-
Merck KGaA
-
Zymo Research Corporation
-
Active Motif, Inc.
-
Thermo Fisher Scientific Inc.
-
Diagenode S.A.
-
Chroma Therapeutics Ltd.
-
Syndax Pharmaceuticals, Inc.
Key Developments:
-
March 2024: Illumina, Inc. introduces a new high-throughput sequencing platform intended exclusively for epigenetic research, allowing for more complete methylation profiling.
-
In January 2024, Qiagen N.V. announced a collaboration with a renowned pharmaceutical company to develop companion diagnostics for a revolutionary epigenetic therapy for solid tumours.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Illumina, Inc.
5.2. Qiagen N.V.
5.3. Abcam plc
5.4. Merck KGaA
5.5. Zymo Research Corporation
5.6. Active Motif, Inc.
5.7. Thermo Fisher Scientific Inc.
5.8. Diagenode S.A.
5.9. Chroma Therapeutics Ltd.
5.10. Syndax Pharmaceuticals, Inc. (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Increasing prevalence of cancer driving demand for epigenetic therapies
6.1.2. Integration of AI and machine learning in epigenetic research
6.1.3. Development of epigenetic biomarkers for early disease detection
6.2. Market Drivers
6.2.1. Advancements in diagnostic technologies enhancing epigenetic research and clinical applications
6.2.2. Rising adoption of personalized medicine
6.2.3. Increasing investments in drug discovery and development
6.3. Market Restraints
6.3.1. Regulatory challenges and high development costs hindering market growth
6.3.2. Complexity of epigenetic mechanisms and potential off-target effects
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. HDAC Inhibitors
7.2. DNMT Inhibitors
7.3. Others
7.3.1. HMT Inhibitors
7.3.2. HDM Inhibitors
8. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Oncology
8.2. Metabolic Disorders
8.3. Autoimmune Disorders
8.4. Others
8.4.1. Cardiovascular Diseases
8.4.2. Neurological Disorders
9. BY DIAGNOSTIC TECHNOLOGY (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. PCR-based
9.2. Sequencing-based
9.3. Immunoassays
9.4. Others
9.4.1. Microarrays
9.4.2. Mass Spectrometry
10. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Hospitals
10.2. Specialty Clinics
10.3. Research Institutes
10.4. Others
10.4.1. Pharmaceutical Companies
10.4.2. Diagnostic Laboratories
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
Market Segmentation:
By Drug Type:
-
HDAC Inhibitors
-
DNMT Inhibitors
-
Others
-
HMT Inhibitors
-
HDM Inhibitors
-
By Application:
-
Oncology
-
Metabolic Disorders
-
Autoimmune Disorders
-
Others
-
Cardiovascular Diseases
-
Neurological Disorders
-
By Diagnostic Technology:
-
PCR-based
-
Sequencing-based
-
Immunoassays
-
Others
-
Microarrays
-
Mass Spectrometry
-
By End User:
-
Hospitals
-
Specialty Clinics
-
Research Institutes
-
Others
-
Pharmaceutical Companies
-
Diagnostic Laboratories
-
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511